First Heartland Consultants’s West Pharmaceutical WST Stock Holding History

First Heartland Consultants’s Portfolio WST Stock Details WST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$200K	Buy	+558	New	+$171K	0.01%	576

Other funds holding WST

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

Vest Financial Mclean, Virginia $9.52B AUM 31.6% 1-Year Est. Return

Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return

AMI Asset Management Los Angeles, California $1.74B AUM 26.89% 1-Year Est. Return

Seilern Investment Management London, United Kingdom $794M AUM 6.63% 1-Year Est. Return

Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

Ninety One (UK)

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

Assenagon Asset Management

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

North Growth Management Vancouver, British Columbia, Canada $780M AUM 102.77% 1-Year Est. Return

First Heartland Consultants's WST Position: Q2 2026 in Review

First Heartland Consultants opened a new position in West Pharmaceutical (WST) in Q2 2026: 558 shares worth $200K. The stake represents 0.01% of the portfolio and ranks #576 among its holdings.

189 funds tracked by Wall St. Rank hold WST as of Q2 2026.

First Heartland Consultants held 558 shares of West Pharmaceutical worth $200K as of Q2 2026.
West Pharmaceutical was a new First Heartland Consultants position in Q2 2026.
West Pharmaceutical made up 0.01% of First Heartland Consultants's portfolio in Q2 2026, its #576 holding.
189 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2026.

Based on First Heartland Consultants's 13F filing for Q2 2026, filed 8 Jul 2026.